CoChat
Sign Up
Cited by 214Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsLipoproteins and Cardiovascular Health

Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older Individuals

Open access
Song, Fei, Poljak, Anne, Crawford, John, Kochan, Nicole A., Wen, Wei, Cameron, Barbara, Lux, Ora, Brodaty, Henry +3 more·2012·PLoS ONE
DOI 10.1371/journal.pone.0034078PMC PMC3372509
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVES: Apolipoproteins have recently been implicated in the etiology of Alzheimer's disease (AD). In particular, Apolipoprotein J (ApoJ or clusterin) has been proposed as a biomarker of the disease at the pre-dementia stage. We examined a group of apolipoproteins, including ApoA1, ApoA2, ApoB, ApoC3, ApoE, ApoH and ApoJ, in the plasma of a longitudinal community based cohort. METHODS: 664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. RESULTS: At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio. Carriers of the apolipoprotein E ε4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB. Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels. ApoJ and ApoE levels were correlated negatively with grey matter volume and positively with cerebrospinal fluid (CSF) volume on MRI. Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitively normal individuals. ApoA1 was the most significant predictor of decline. These associations remained after statistically controlling for lipid profile. Higher ApoJ levels predicted white matter atrophy over two years. CONCLUSIONS: Elderly individuals with MCI have abnormal apolipoprotein levels, which are related to cognitive function and volumetric MRI measures cross-sectionally and are predictive of cognitive impairment in cognitively normal subjects. ApoA1, ApoH and ApoJ are potential plasma biomarkers of cognitive decline in non-demented elderly individuals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0034078

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Higher levels of plasma apoB are associated with AD or cognitive decline.

    “Higher levels of plasma apoB are associated with AD or cognitive decline [9, 10]”

    From Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants (2023) · cites this paper as [9]

    The Discussion section (‘ApoA1, ApoB and Cognitive Decline’; page unavailable) reports that ApoB is increased in AD plasma, supporting the AD part of the claim. The paper’s own Results (‘Apolipoprotein Levels to Predict Future Cognitive Decline’; page unavailable) do not show a significant association between ApoB alone and subsequent cognitive decline; they show one for the ApoB/ApoA1 ratio. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 71

  1. [2]Petersen RC 2004 Mild cognitive impairment as a diagnostic entity. J Intern Med 256 183 194 15324362
  2. [3]Ganguli M Dodge HH Shen C DeKosky ST 2004 Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 63 115 121 15249620
  3. [4]Petersen RC Doody R Kurz A Mohs RC Morris JC 2001 Current concepts in mild cognitive impairment. Arch Neurol 58 1985 1992 11735772
  4. [5]Rountree SD Waring SC Chan WC Lupo PJ Darby EJ 2007 Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement Geriatr Cogn Disord 24 476 482 17992015
  5. [6]Boyle PA Wilson RS Aggarwal NT Tang Y Bennett DA 2006 Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 67 441 445 16894105
  6. [7]Jellinger KA Mitter-Ferstl E 2003 The impact of cerebrovascular lesions in Alzheimer disease–a comparative autopsy study. J Neurol 250 1050 1055 14504965
  7. [8]Laukka EJ Fratiglioni L Backman L 2010 The influence of vascular disease on cognitive performance in the preclinical and early phases of Alzheimer’s disease. Dement Geriatr Cogn Disord 29 498 503 20523048
  8. [9]Kivipelto M Helkala EL Laakso MP Hanninen T Hallikainen M 2001 Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322 1447 1451 11408299 PMC32306
  9. [10]Whitmer RA Sidney S Selby J Johnston SC Yaffe K 2005 Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64 277 281 15668425
  10. [11]Alonso A Jacobs DR Jr Menotti A Nissinen A Dontas A 2009 Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J Neurol Sci 280 79 83 19251275
  11. [12]Martins IJ Hone E Foster JK Sunram-Lea SI Gnjec A 2006 Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry 11 721 736 16786033
  12. [13]Dufouil C Richard F Fievet N Dartigues JF Ritchie K 2005 APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 64 1531 1538 15883313
  13. [14]Sparks DL Sabbagh MN Connor DJ Lopez J Launer LJ 2005 Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 753 757 15883262
  14. [15]Millan J Pinto X Munoz A Zuniga M Rubies-Prat J 2009 Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 5 757 765 19774217 PMC2747394
  15. [16]Eichner JE Dunn ST Perveen G Thompson DM Stewart KE 2002 Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155 487 495 11882522
  16. [17]Takechi R Galloway S Pallebage-Gamarallage MM Wellington CL Johnsen RD 2010 Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta. Br J Nutr 103 652 662 19860996
  17. [18]Lewis TL Cao D Lu H Mans RA Su YR 2010 Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 285 36958 36968 20847045 PMC2978624
  18. [19]Katzav A Faust-Socher A Kvapil F Michaelson DM Blank M 2011 Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging 32 272 279 19282067
  19. [20]Thambisetty M Simmons A Velayudhan L Hye A Campbell J 2010 Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67 739 748 20603455 PMC3111021
  20. [21]Kawano M Kawakami M Otsuka M Yashima H Yaginuma T 1995 Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer/s disease. Clin Chim Acta 239 209 211 8542660
  21. [22]Bereczki E Bernat G Csont T Ferdinandy P Scheich H 2008 Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. J Proteome Res 7 2246 2252 18473452
  22. [23]Caramelli P Nitrini R Maranhao R Lourenco AC Damasceno MC 1999 Increased apolipoprotein B serum concentration in Alzheimer/s disease. Acta Neurol Scand 100 61 63 10416513
  23. [24]Zhang R Barker L Pinchev D Marshall J Rasamoelisolo M 2004 Mining biomarkers in human sera using proteomic tools. Proteomics 4 244 256 14730686
  24. [25]Scacchi R De Bernardini L Mantuano E Vilardo T Donini LM 1998 DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer’s disease. Dement Geriatr Cogn Disord 9 186 190 9681639
  25. [26]van Dijk KW Rensen PC Voshol PJ Havekes LM 2004 The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism? Curr Opin Lipidol 15 239 246 15166778
  26. [27]Petersen RC Smith GE Ivnik RJ Tangalos EG Schaid DJ 1995 Apolipoprotein E status as a predictor of the development of Alzheimer’s disease in memory-impaired individuals. JAMA 273 1274 1278 7646655
  27. [28]Saunders AM Strittmatter WJ Schmechel D George-Hyslop PH Pericak-Vance MA 1993 Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43 1467 1472 8350998
  28. [29]Gupta VB Laws SM Villemagne VL Ames D Bush AI 2011 Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 76 1091 1098 21422459
  29. [30]Pirttila T Koivisto K Mehta PD Reinikainen K Kim KS 1998 Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer’s disease. Neurosci Lett 249 21 24 9672379
  30. [31]Siest G Bertrand P Qin B Herbeth B Serot JM 2000 Apolipoprotein E polymorphism and serum concentration in Alzheimer’s disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med 38 721 730 11071064
  31. [32]Slooter AJ de Knijff P Hofman A Cruts M Breteler MM 1998 Serum apolipoprotein E level is not increased in Alzheimer’s disease: the Rotterdam study. Neurosci Lett 248 21 24 9665654
  32. [33]Hesse C Larsson H Fredman P Minthon L Andreasen N 2000 Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 25 511 517 10823584
  33. [34]Darreh-Shori T Forsberg A Modiri N Andreasen N Blennow K 2011 Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer’s disease in the brain in vivo. Neurobiol Aging 32: 2320 e2315–2332 20538374
  34. [35]Darreh-Shori T Modiri N Blennow K Baza S Kamil C 2011 The apolipoprotein E epsilon4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 32 1236 1248 19713000
  35. [36]Lindh M Blomberg M Jensen M Basun H Lannfelt L 1997 Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer’s disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett 229 85 88 9223597
  36. [37]Leduc MS Shimmin LC Klos KL Hanis C Boerwinkle E 2008 Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA. J Lipid Res 49 2648 2656 18676959 PMC2582370
  37. [38]Ohrfelt A Andreasson U Simon A Zetterberg H Edman A 2011 Screening for new biomarkers for subcortical vascular dementia and Alzheimer’s disease. Dement Geriatr Cogn Dis Extra 1 31 42 22163231 PMC3199889
  38. [40]Lambert JC Heath S Even G Campion D Sleegers K 2009 Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 41 1094 1099 19734903
  39. [41]Nuutinen T Suuronen T Kauppinen A Salminen A 2009 Clusterin: a forgotten player in Alzheimer’s disease. Brain Res Rev 61 89 104 19651157
  40. [42]Sachdev PS Brodaty H Reppermund S Kochan NA Trollor JN 2010 The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70–90 years. Int Psychogeriatr 1 17 20637138
  41. [43]Folstein MF Folstein SE McHugh PR 1975 “Mini-mental state” J Psychiatr Res 12 189 198 A practical method for grading the cognitive state of patients for the clinician. 1202204
  42. [44]Anderson TM Sachdev PS Brodaty H Trollor JN Andrews G 2007 Effects of sociodemographic and health variables on Mini-Mental State Exam scores in older Australians. Am J Geriatr Psychiatry 15 467 476 17545447
  43. [45]Winblad B Palmer K Kivipelto M Jelic V Fratiglioni L 2004 Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256 240 246 15324367
  44. [47]Hindmarch I Lehfeld H de Jongh P Erzigkeit H 1998 The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 9 20 26 9718231
  45. [48]Morris JC 1993 The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 2412 2414 8232972
  46. [49]Jorm AF Mather KA Butterworth P Anstey KJ Christensen H 2007 APOE genotype and cognitive functioning in a large age-stratified population sample. Neuropsychology 21 1 8 17201525
  47. [50]Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 28 463 469 20458316
  48. [51]O’Bryant SE Xiao G Barber R Reisch J Doody R 2010 A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67 1077 1081 20837851 PMC3069805
  49. [54]Gupta VB Laws SM Villemagne VL Ames D Bush AI 2011 Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging. Neurology 76 1091 1098 21422459
  50. [55]Liu HC Hu CJ Chang JG Sung SM Lee LS 2006 Proteomic identification of lower apolipoprotein A-I in Alzheimer’s disease. Dement Geriatr Cogn Disord 21 155 161 16391478
  51. [56]Merched A Xia Y Visvikis S Serot JM Siest G 2000 Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol Aging 21 27 30 10794845
  52. [57]Roher AE Maarouf CL Sue LI Hu Y Wilson J 2009 Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer’s disease. Biomarkers Epub ahead of print PMC2824250 19863188
  53. [58]Sherman CB Peterson SJ Frishman WH 2010 Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 18 141 147 20395699
  54. [59]Kuo YM Emmerling MR Bisgaier CL Essenburg AD Lampert HC 1998 Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain abeta 1–42 levels. Biochem Biophys Res Commun 252 711 715 9837771
  55. [60]Takechi R Galloway S Pallebage-Gamarallage M Wellington C Johnsen R 2009 Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. Histochem Cell Biol 131 661 666 19225804
  56. [61]Martins IJ Berger T Sharman MJ Verdile G Fuller SJ 2009 Cholesterol metabolism and transport in the pathogenesis of Alzheimer’s disease. J Neurochem 111 1275 1308 20050287
  57. [62]Darreh-Shori T Siawesh M Mousavi M Andreasen N Nordberg A 2011 Apolipoprotein epsilon4 Modulates Phenotype of Butyrylcholinesterase in CSF of Patients with Alzheimer’s Disease. J Alzheimers Dis 28 443 458 22012848
  58. [63]de Laat B Derksen RH van Lummel M Pennings MT de Groot PG 2006 Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 107 1916 1924 16269621
  59. [64]Castro A Lazaro I Selva DM Cespedes E Girona J 2010 APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. Atherosclerosis 209 201 205 19878946
  60. [65]George D Erkan D 2009 Antiphospholipid syndrome. Prog Cardiovasc Dis 52 115 125 19732604
  61. [66]Ruiz-Irastorza G Khamashta MA Hughes GR 2002 Hughes syndrome crosses boundaries. Autoimmun Rev 1 43 48 12849057
  62. [67]de Silva HV Harmony JA Stuart WD Gil CM Robbins J 1990 Apolipoprotein J: structure and tissue distribution. Biochemistry 29 5380 5389 1974459
  63. [68]Jordan-Starck TC Lund SD Witte DP Aronow BJ Ley CA 1994 Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J Lipid Res 35 194 210 8169523
  64. [69]Choi-Miura NH Ihara Y Fukuchi K Takeda M Nakano Y 1992 SP-40,40 is a constituent of Alzheimer’s amyloid. Acta Neuropathol 83 260 264 1373021
  65. [70]Ghiso J Matsubara E Koudinov A Choi-Miura NH Tomita M 1993 The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293 (Pt 1) 27 30 PMC1134315 8328966
  66. [71]Zlokovic BV Martel CL Matsubara E McComb JG Zheng G 1996 Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93 4229 4234 8633046 PMC39517
  67. [72]Lidstrom AM Bogdanovic N Hesse C Volkman I Davidsson P 1998 Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease. Exp Neurol 154 511 521 9878186
  68. [73]Giannakopoulos P Kovari E French LE Viard I Hof PR 1998 Possible neuroprotective role of clusterin in Alzheimer’s disease: a quantitative immunocytochemical study. Acta Neuropathol 95 387 394 9560017
  69. [74]Kullberg S Aldskogius H Ulfhake B 2001 Microglial activation, emergence of ED1-expressing cells and clusterin upregulation in the aging rat CNS, with special reference to the spinal cord. Brain Res 899 169 186 11311878
  70. [75]Nilselid AM Davidsson P Nagga K Andreasen N Fredman P 2006 Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int 48 718 728 16490286
  71. [76]Sihlbom C Davidsson P Sjogren M Wahlund LO Nilsson CL 2008 Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer’s disease patients and healthy individuals. Neurochem Res 33 1332 1340 18288611

Cited by

Sorted by citations

Authors
Song, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., Lux, O., Brodaty, H., Mather, K., Smythe, G. A., & Sachdev, P. S.
Affiliations
UNSW Sydney (AU)
Corresponding author
Sachdev, Perminder S.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-06-11
Volume
7
Issue
6
Pages
e34078
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0034078
PMC
PMC3372509
OpenAlex
W2011267119
Cited by
214
References
2
Citations by year
2026: 9 · 2025: 12 · 2024: 16 · 2023: 14 · 2022: 13 · 2021: 19 · 2020: 17 · 2019: 19 · 2018: 12 · 2017: 23 · 2016: 12 · 2015: 18 · 2014: 17 · 2013: 13
FWCI
10.97
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Neuroscience Research Australia
  • Medical Research Council (350833)
  • National Health and Medical Research Council (568940, 350833)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
plasma apolipoproteins, cognitive decline, mild cognitive impairment, Alzheimer's disease, APOE ε4, apolipoprotein A-I, beta2-glycoprotein I, plasma biomarkers, white matter atrophy, gray matter volume, cerebrospinal fluid volume, older adults
MeSH terms
Aged, Aged, 80 and over, Analysis of Variance, Apolipoproteins, Humans, Longitudinal Studies, New South Wales, Fluoroimmunoassay, Cohort Studies, Linear Models, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review